Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 02 2017 - 4:05PM
Business Wire
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer
of investigational RNA interference (RNAi) therapeutics, today
announced that on January 31, 2017, the Compensation Committee of
the Company's Board of Directors approved the grant of an
inducement stock option to purchase a total of 75,000 shares of
common stock to one new employee, with a grant date of January 31,
2017 (the "Inducement Grant").
The Inducement Grant was granted pursuant to Dicerna’s 2016
Inducement Plan and has an exercise price per share equal to $2.49,
the fair market value on the grant date. The stock option vests
over four years, with 25% vesting on the one-year anniversary of
the employee's first day of employment with the Company and 1/36 of
the remaining shares vesting monthly thereafter, subject to the new
employee's continued service relationship with the Company on each
such date. The stock option has a 10-year term and is subject to
the terms and conditions of the applicable stock option
agreement.
The stock option was granted as an inducement material to the
new employee entering into employment with Dicerna Pharmaceuticals,
Inc. in accordance with NASDAQ listing Rule 5635(c)(4).
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the discovery and development of innovative RNA
interference (RNAi)-based therapeutics for diseases involving the
liver, including rare diseases, chronic liver diseases,
cardiovascular diseases, and viral infectious diseases. The Company
is leveraging its proprietary GalXC™ RNAi technology platform to
build a broad pipeline in these core therapeutic areas, focusing on
target genes where connections between these genes and diseases are
well understood and documented. The Company intends to discover,
develop and commercialize novel therapeutics either on its own or
in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statements. Applicable risks and
uncertainties include those relating to our preclinical research
and other risks identified under the heading "Risk Factors"
included in our most recent Form 10-Q filing and in other future
filings with the SEC. The forward-looking statements contained in
this press release reflect Dicerna's current views with respect to
future events, and Dicerna does not undertake and specifically
disclaims any obligation to update any forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170202006242/en/
Investors:Rx Communications GroupMelody Carey,
917-322-2571mcarey@rxir.comorMedia:SmithSolveAlex Van Rees,
973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024
